var data={"title":"Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/701790?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Patient drug information&quot;</a> and <a href=\"topic.htm?path=fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48869238\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Death in preterm infants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Deaths in preterm infants after infusion of intravenous (IV) lipid emulsions have been reported in the medical literature. Autopsy findings included intravascular fat accumulation in the lungs. Preterm infants and low-birth-weight infants have poor clearance of IV lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47022752\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Smoflipid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22549120\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Smoflipid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22788843\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Caloric Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781932\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Caloric/fatty acid source:</b> IV: 1 to 2 g/kg/day; daily dose may be infused over 12 to 24 hours; maximum: 2.5 g/kg/day. <b>Note:</b> Fat emulsion should not exceed 60% of the total daily calories. At the onset of therapy, observe patient for any immediate allergic reactions (eg, dyspnea, cyanosis, fever).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Serious hemodynamic or other instability secondary to highly lipid soluble substances (off-label use): Note:</b> Continue chest compressions during administration (lipid must circulate): 20%: IV: 1.5 <b>mL</b>/kg administered over 1 to 3 minutes, followed immediately by an infusion of 0.25 <b>mL</b>/kg/minute (recommended infusion durations vary; see below); may repeat the bolus as necessary for persistent cardiovascular collapse or if instability re-emerges (ACMT 2016; Lavonas [AHA] 2015; Neal [ASRA] 2012). Suggested maximum dose: 10 <b>mL</b>/kg over the first 30 to 60 minutes (Lavonas [AHA] 2015; Neal [ASRA] 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">After administration of the initial bolus and continuous infusion, recommendations regarding the continuous infusion vary significantly:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>American College of Medical Toxicology:</i> If after the bolus and continuing the infusion for 3 minutes, the patient demonstrates a significant response, the infusion rate may be reduced to 0.025 <b>mL</b>/kg/minute (ie, one-tenth the initial rate). If instability re-emerges, the infusion rate may be increased back to 0.25 <b>mL</b>/kg/minute or the bolus may be repeated (ACMT 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>American Heart Association recommendations:</i> Continue infusion for 30 to 60 minutes (Lavonas [AHA] 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>American Society of Regional Anesthesia and Pain Medicine:</i> Continue infusion for at least 10 minutes after hemodynamic stability has been restored. Increase the infusion rate to 0.5 <b>mL</b>/kg/minute if hemodynamic instability persists or recurs. (Neal [ASRA] 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781933\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Energy expenditure and requirements may be lower in these patients; refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781934\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781935\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47022753\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Smoflipid: 20% (100 mL, 250 mL, 500 mL) [contains egg phospholipids (egg lecithin)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47022751\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781979\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Emulsion, Intravenous:</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">Smoflipid 20%: Soybean oil 6%, medium chain triglycerides 6%, olive oil 5%, and fish oil 3% (100 mL, 250 mL, 500 mL) [contains egg phospholipids]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781948\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer by IV infusion via peripheral line or central venous infusion using DEHP-free administration sets and lines. Initial rate of infusion should be 0.5 mL/minute for the first 15 to 30 minutes; gradually increase until reaching the required rate after 30 minutes as tolerated. Do not exceed a rate of 0.5 mL/kg/hour. May be simultaneously infused with amino acid dextrose mixtures by means of Y-connector located near infusion site (flow rates of each solution should be controlled separately by infusion pumps). When administered with dextrose and amino acids, the choice of a central or peripheral infusion depends on the osmolarity of the final infusate (osmolarity &ge;900 mOsm/L must be infused through a central vein). All fat emulsion infusions should be filtered whether part of an admixture or infused separately using a 1.2-micron in-line filter only (ISMP 2016). To prevent air embolism, use a nonvented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible bags in series, fully evacuate residual gas in the bag prior to administration, do not pressurize the flexible bag to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the bag runs dry.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Serious hemodynamic or other instability secondary to highly lipid soluble substances (off-label use):</i> Administer initial bolus over 1 to 3 minutes followed by a continuous infusion. Chest compressions should continue during administration if patient is in cardiac arrest. Some experts recommend a decreased infusion rate in patients who respond favorably to the initial bolus and infusion (ACMT 2016); repeat bolus or an increase in the infusion rate may be considered if instability persists or recurs. (ACMT 2016; Lavonas [AHA] 2015; Neal [ASRA] 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22549121\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Caloric/fatty acid source:</b> Source of calories, essential fatty acids, and omega-3 fatty acids for adults requiring parenteral nutrition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25976338\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Serious hemodynamic or other instability secondary to highly lipid soluble substances</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22801480\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (3%), tachycardia (&le;1%), thrombophlebitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&le;1%), headache (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (&le;1%), skin rash (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia (5%), increased serum triglycerides (3%), increased gamma-glutamyl transferase (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (9%), vomiting (7%), abdominal pain (4%), flatulence (4%), dyspepsia (2%), cholestasis (&le;1%), diarrhea (&le;1%), dysgeusia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (2%), C-reactive protein increased (&le;1%), leukocytosis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (&le;1%), increased serum alkaline phosphatase (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Catheter infection (2%), sepsis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (&le;1%), pneumonia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781923\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to fish, egg, soybean, or any other component of the formulation; severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentrations &gt;1,000 mg/dL). <b>Note:</b> Although the manufacturer's labeling lists hypersensitivity to peanut protein as a contraindication, the product does not contain peanut protein. However, a low risk of cross-reactivity between soy and peanuts may exist.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe hepatic insufficiency; severe blood coagulation disorders; severe renal insufficiency without access to hemofiltration or dialysis; acute shock; acute pulmonary edema; hyperhydration; decompensated cardiac insufficiency; unstable conditions (eg, severe post-traumatic conditions, uncompensated diabetes mellitus, acute MI, CVA, embolism, metabolic acidosis, severe sepsis, hypotonic dehydration)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781924\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fat overload syndrome: Although rare, a reduced or limited ability to metabolize lipids accompanied by prolonged plasma clearance resulting in a sudden deterioration in the patient's condition accompanied by fever, anemia, leukopenia, thrombocytopenia, coagulation disorders, hyperlipidemia, liver fatty infiltration (hepatomegaly), deteriorating liver function, and CNS (eg, coma) may occur; usually reversible upon discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Although the exact etiology is unknown and likely multifactorial, parenteral nutrition associated liver disease (PNALD) has been reported in patients receiving parenteral nutrition for extended periods of time, especially preterm infants, and can present as cholestasis or steatohepatitis, fibrosis and cirrhosis, possibly leading to hepatic failure; cholecystitis and cholelithiasis have also been observed. Consider discontinuation or dose reduction in patients who develop abnormal LFTs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Contains soybean oil, fish oil, and egg phospholipids; hypersensitivity reactions may occur. Cross sensitivity has been observed between soybean and peanut. Discontinue use immediately if a reaction occurs and treat appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertriglyceridemia: Impaired lipid metabolism with hypertriglyceridemia may occur in conditions such as inherited lipid disorders, obesity, diabetes mellitus, and metabolic syndrome. Obtain baseline serum triglycerides before initiating therapy, at the time of each dosage increase, and regularly throughout treatment. In adults with triglycerides &gt;400 mg/dL, reduce the dose and monitor triglycerides.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Refeeding syndrome: Refeeding severely undernourished patients with parenteral nutrition may result in the refeeding syndrome (eg, intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic); thiamine deficiency and fluid retention may also develop. Carefully monitor severely undernourished patients and slowly increase their nutrient intakes, while avoiding overfeeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anemia: The use of fat emulsion has been associated with anemia likely due to hemodilution (Zellner 1967). Use with caution in patients with anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fat embolism: Use with caution in patients who may be at danger for fat embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: Use with caution in patients with pancreatitis without hyperlipidemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may contain aluminum, which may accumulate following prolonged administration in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Toxicity secondary to highly lipid soluble substances: Hemodynamic and other instability: Successful resuscitation following the administration of fat emulsion has been reported in animal studies and several human case reports in which cardiovascular toxicity was unresponsive to conventional resuscitation and antidotal measures. Successful resuscitation following the administration of fat emulsion has been reported in pediatric patients (Fuzaylov 2010; Ludot 2008; Shah 2009; Wong 2010). Additional information is available at http://www.lipidrescue.org. Consider use when toxicity secondary to a highly lipid soluble substance is likely and conventional methods are unsuccessful. Continue CPR throughout treatment with lipid emulsion. Consultation with a medical toxicologist or poison control center is highly recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Energy expenditure and requirements may be lower in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; <b>Pediatric [US Boxed Warning]: Deaths in preterm infants following administration of fat emulsion have been reported; autopsy findings included intravascular fat accumulation in the lungs. Premature infants, low-birth-weight infants, and small-for-gestational-age infants clear intravenous fat emulsion poorly and have increased free fatty acid plasma levels following fat emulsion infusion.</b> The safe and effective use in pediatric patients, including preterm infants, has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum: May contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal impairment. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: The too-rapid administration of fat emulsion can cause fluid and/or fat overloading, resulting in dilution of serum electrolyte concentrations, overhydration, congested states, pulmonary edema, impaired pulmonary diffusion capacity, or metabolic acidosis; hourly infusion rate should be as low as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Simultaneous infusion of a carbohydrate/amino acid solution is recommended to minimize the risk of metabolic acidosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Three-in-one mixtures: Lipid emulsion in a three-in-one mixture may obscure the presence of a precipitate; follow compounding guidelines, especially for calcium and phosphate additions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47086803\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47086800\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=91658&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Fat Emulsion (Fish Oil and Plant Based) may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781921\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Severe maternal malnutrition may cause adverse events to the fetus/neonate. Indications for fat emulsion therapy in pregnant women are the same as in nonpregnant women. The ASPEN guidelines for parenteral and enteral nutrition state that intravenous fat emulsion may be used safely in pregnant women to provide calories and prevent essential fatty acid deficiency (ASPEN Guidelines 2002). Fat emulsion therapy has been used successfully in the resuscitation of a pregnant female with suspected bupivacaine toxicity (Spence 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781922\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if fat emulsion (fish oil based) is excreted in breast milk. The fatty acids found in fat emulsion (eg, linoleic acid, linolenic acid) are endogenous to human milk and concentrations are influenced by maternal diet (IOM 2005). According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781938\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caloric content: 2 kcal/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus: 15 mmol/L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fat emulsion should not exceed 60% of the total daily calories.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781951\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-left:0em;\">Monitor for signs and symptoms of infection (including vascular access device complications); fluid and electrolyte status; serum osmolarity; blood glucose; blood counts (including platelets and coagulation parameters); signs and symptoms of essential fatty acid deficiency, fat overload, refeeding syndrome, and/or hypersensitivity reactions.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Monitor hepatic and renal function tests periodically. Monitor triglycerides before initiation of therapy and at least weekly during therapy (or until triglycerides are stable and when changes are made in the amount of fat administered; ASPEN Guidelines 2002); monitor especially closely in patients with pancreatitis or hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781927\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fat emulsion is metabolized and utilized as an energy source; provides fatty acids (linoleic acid, oleic acid, caprylic acid, palmitic acid, capric acid, stearic acid, and alpha linolenic acid) and omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) necessary for normal structure and function of cell membranes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In toxicity secondary to highly lipid soluble substances, exogenous lipids provide an alternative source of binding (Rowlingson 2008), commonly known as the &quot;lipid sink&quot; effect. High lipid partition constant and large volumes of distribution are good predictors of success when using lipid therapy (French 2011). Lipid administration may also affect the heart in a metabolically advantageous way by improving fatty acid transport (Weinberg 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781929\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Fatty acids, phospholipids, and glycerol are metabolized by cells to adenosine triphosphate (ATP), carbon dioxide, and water</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Biliary (phospholipids)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48851915\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (SMOFlipid Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (250 mL): $27.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50168918\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Smoflipid (AR, AT, CR, CZ, DE, DK, DO, EE, ES, FR, GT, HK, HN, HR, HU, IL, KR, LB, LT, LV, MX, NI, NO, NZ, PA, PL, PT, RO, SI, SK, SV, UA, UY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27121236\"></a>American College of Medical Toxicology (ACMT). ACMT Position Statement: Guidance for the Use of Intravenous Lipid Emulsion [published online ahead of print April 27, 2016]. <i>J Med Toxicol</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/27121236/pubmed\" target=\"_blank\" id=\"27121236\">27121236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23186600\"></a>Arora NP, Berk WA, Aaron CK, Williams KA. Usefulness of intravenous lipid emulsion for cardiac toxicity from cocaine overdose. <i>Am J Cardiol</i>. 2013;111(3):445-447.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/23186600/pubmed\" target=\"_blank\" id=\"23186600\">23186600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. <i>JPEN J Parenter Enteral Nutr</i>. 2002;26(1 Suppl):1-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/11841046/pubmed\" target=\"_blank\" id=\"11841046\">11841046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Carr.2009a\"></a>Carr D, Boone A, Hoffman RS, et al. Successful resuscitation of a carvedilol overdose using intravenous fat emulsion. <i>Clin Toxicol</i>. 2009a;47(7):727.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Carr.2009b\"></a>Carr D, Boone A, Hoffman RS, et al. Successful resuscitation of a doxepin overdose using intravenous fat emulsion. <i>Clin Toxicol</i>. 2009b;47(7):710.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21621362\"></a>Castanares-Zapatero D, Wittebole X, Huberlant V, Morunglav M, Hantson P. Lipid emulsion as rescue therapy in lamotrigine overdose. <i>J Emerg Med</i>. 2012;42(1):48-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/21621362/pubmed\" target=\"_blank\" id=\"21621362\">21621362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19892505\"></a>Cohen V, Jellinek SP, Stansfield L, Truong H, Baseluos C, Marshall JP. Cardiac arrest with residual blindness after overdose of Tessalon&reg; (benzonatate) perles. <i>J Emerg Med</i>. 2011;41(2):166-171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/19892505/pubmed\" target=\"_blank\" id=\"19892505\">19892505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21068706\"></a>Dagtekin O, Marcus H, M&uuml;ller C, B&ouml;ttiger BW, Sp&ouml;hr F. Lipid therapy for serotonin syndrome after intoxication with venlafaxine, lamotrigine and diazepam. <i>Minerva Anestesiol</i>. 2011;77(1):93-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/21068706/pubmed\" target=\"_blank\" id=\"21068706\">21068706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21263316\"></a>Dix SK, Rosner GF, Nayar M, et al. Intractable cardiac arrest due to lidocaine toxicity successfully resuscitated with lipid emulsion. <i>Crit Care Med</i>. 2011;39(4):872-874.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/21263316/pubmed\" target=\"_blank\" id=\"21263316\">21263316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19143698\"></a>Finn SD, Uncles DR, Willers J, Sable N. Early treatment of a quetiapine and sertraline overdose with Intralipid. <i>Anaesthesia</i>. 2009;64(2):191-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/19143698/pubmed\" target=\"_blank\" id=\"19143698\">19143698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17448066\"></a>Foxall G, McCahon R, Lamb J, Hardman JG, Bedforth NM. Levobupivacaine-induced seizures and cardiovascular collapse treated with Intralipid. <i>Anaesthesia</i>. 2007;62(5):516-518.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/17448066/pubmed\" target=\"_blank\" id=\"17448066\">17448066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21320947\"></a>Franxman TJ, Al-Nabhan M, Cavallazzi RS, Speak AJ. Lipid emulsion therapy for verapamil overdose. <i>Ann Intern Med</i>. 2011;154(4):292.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/21320947/pubmed\" target=\"_blank\" id=\"21320947\">21320947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21563913\"></a>French D, Armenian P, Ruan W, et al. Serum verapamil concentrations before and after Intralipid&reg; therapy during treatment of an overdose. <i>Clin Toxicol (Phila)</i>. 2011;49(4):340-344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/21563913/pubmed\" target=\"_blank\" id=\"21563913\">21563913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    French D, Smollin C, Ruan W, et al. Partition constant and volume of distribution as predictors of clinical efficacy of lipid rescue for toxicological emergencies. <i>Clin Toxicol</i>. 2011;49(9):801-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/21981684/pubmed\" target=\"_blank\" id=\"21981684\">21981684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuzaylov G, Ying B, Tang Y, Sethna NF. Successful resuscitation after inadvertent intravenous injection of bupivacaine in an adolescent. <i>Paediatr Anaesth</i>. 2010;20(10):958-959.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/20849502/pubmed\" target=\"_blank\" id=\"20849502\">20849502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21989640\"></a>Geib AJ, Liebelt E, Manini AF; Toxicology Investigators' Consortium (ToxIC). Clinical experience with intravenous lipid emulsion for drug-induced cardiovascular collapse. <i>J Med Toxicol</i>. 2012;8(1):10-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/21989640/pubmed\" target=\"_blank\" id=\"21989640\">21989640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20090535\"></a>Hillyard SG, Barrera-Groba C, Tighe R. Intralipid reverses coma associated with zopiclone and venlafaxine overdose. <i>Eur J Anaesthesiol</i>. 2010;27(6):582-583.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/20090535/pubmed\" target=\"_blank\" id=\"20090535\">20090535</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine). <i>Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)</i>. Washington, DC: The National Academies Press, 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22074030\"></a>Jakkala-Saibaba R, Morgan PG, Morton GL. Treatment of cocaine overdose with lipid emulsion. <i>Anaesthesia</i>. 2011;66(12):1168-1170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/22074030/pubmed\" target=\"_blank\" id=\"22074030\">22074030</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21740142\"></a>Jovic-Stosic J, Gligic B, Putic V, Brajkovic G, Spasic R. Severe propranolol and ethanol overdose with wide complex tachycardia treated with intravenous lipid emulsion: a case report. <i>Clin Toxicol (Phila)</i>. 2011;49(5):426-430.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/21740142/pubmed\" target=\"_blank\" id=\"21740142\">21740142</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24197589\"></a>Kundu R, Almasri H, Moza A, Ghose A, Assaly R. Intravenous lipid emulsion in wide complex arrhythmia with alternating bundle branch block pattern from cocaine overdose. <i>Kardiol Pol</i>. 2013;71(10):1073-1075.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/24197589/pubmed\" target=\"_blank\" id=\"24197589\">24197589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26472998\"></a>Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiovascular Resuscitation and Emergency Cardiovascular Care [published correction appears in <i>Circulation</i>. 2016]. <i>Circulation</i>. 2015;132(18 suppl 2):S501-S518.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/26472998/pubmed\" target=\"_blank\" id=\"26472998\">26472998</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21854635\"></a>Liang CW, Diamond SJ, Hagg DS. Lipid rescue of massive verapamil overdose: a case report. <i>J Med Case Rep</i>. 2011;5:399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/21854635/pubmed\" target=\"_blank\" id=\"21854635\">21854635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16867094\"></a>Litz RJ, Popp M, Stehr SN, Koch T. Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion. <i>Anaesthesia</i>. 2006;61(8):800-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/16867094/pubmed\" target=\"_blank\" id=\"16867094\">16867094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Lu.2009\"></a>Lu JJ, Hast HA, Erickson TB. Dramatic QTc narrowing after intralipid administration in quetiapine overdose. <i>Clin Toxicol</i>. 2009;47(7):740.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ludot H, Tharin JY, Belouadah M, Mazoit JX, Malinovsky JM. Successful resuscitation after ropivacaine and lidocaine-induced ventricular arrhythmia following posterior lumbar plexus block in a child [published correction appears in <i>Anesth Analg</i>. 2008;107(1):238]. <i>Anesth Analg</i>. 2008;106(5):1572-1574.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/18420879/pubmed\" target=\"_blank\" id=\"18420879\">18420879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Melo Mde S, Bonfim MR, Dreyer E, et al. Hemodynamic changes in lipid emulsion therapy (SMOFlipid) for bupivacaine toxicity in swines. <i>Acta Cir Bras</i>. 2012;27(4):318-324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/22534807/pubmed\" target=\"_blank\" id=\"22534807\">22534807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo J, Canada T, Johnson D, et al. Task Force for the Revision of Safe Practices for Parenteral Nutrition: Safe practices for parenteral nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(6):S39-S70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/15568296/pubmed\" target=\"_blank\" id=\"15568296\">15568296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21088599\"></a>Montiel V, Gougnard T, Hantson P. Diltiazem poisoning treated with hyperinsulinemic euglycemia therapy and intravenous lipid emulsion. <i>Eur J Emerg Med</i>. 2011;18(2):121-123.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/21088599/pubmed\" target=\"_blank\" id=\"21088599\">21088599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22189574\"></a>Neal JM, Mulroy MF, Weinberg GL; American Society of Regional Anesthesia and Pain Medicine. American Society of Regional Anesthesia and Pain Medicine checklist for managing local anesthetic systemic toxicity: 2012 version. <i>Reg Anesth Pain Med</i>. 2012;37(1):16-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/22189574/pubmed\" target=\"_blank\" id=\"22189574\">22189574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Oakes.2009\"></a>Oakes JA, Piquette C, Barthold CL. Successful use of intravenous lipid as adjunctive therapy in a severe calcium channel antagonist poisoning. <i>Clin Toxicol</i>. 2009;47(7):755.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16810015\"></a>Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. <i>Anesthesiology</i>. 2006;105(1):217-218.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/16810015/pubmed\" target=\"_blank\" id=\"16810015\">16810015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlingson JC. Lipid Rescue: A Step Forward in Patient Safety? Likely So! <i>Anesth Analg</i>. 2008;106(5):1333-1336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/18420839/pubmed\" target=\"_blank\" id=\"18420839\">18420839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah S, Gopalakrishnan S, Apuya J, Shah S, Martin T. Use of Intralipid in an infant with impending cardiovascular collapse due to local anesthetic toxicity. <i>J Anesth</i>. 2009;23(3):439-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/19685131/pubmed\" target=\"_blank\" id=\"19685131\">19685131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17766009\"></a>Sirianni AJ, Osterhoudt KC, Calello DP, et al. Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine. <i>Ann Emerg Med</i>. 2008;51(4):412-415, 415.e1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/17766009/pubmed\" target=\"_blank\" id=\"17766009\">17766009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smetzer J, Cohen M, eds. IV fat emulsion needs a filter. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2016;21(1):3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smoflipid (lipid injectable emulsion) [prescribing information]. Uppsala, Sweden; Fresenius Kabi; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spence AG. Lipid reversal of central nervous system symptoms of bupivacaine toxicity. <i>Anesthesiology</i>. 2007;107(3):516-517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/17721262/pubmed\" target=\"_blank\" id=\"17721262\">17721262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Food and Drug Administration. Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR &sect;201.323.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19451589\"></a>Weinberg G, Di Gregorio G, Hiller D, Hewett A, Sirianni A. Reversal of haloperidol-induced cardiac arrest by using lipid emulsion. <i>Ann Intern Med</i>. 2009;150(10):737-738.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/19451589/pubmed\" target=\"_blank\" id=\"19451589\">19451589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinberg GL, Ripper R, Murphy P, et al. Lipid infusion accelerates removal of bupivacaine and recovery from bupivacaine toxicity in the isolated rat heart. <i>Reg Anesth Pain Med</i>. 2006;31(4):296-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/16857549/pubmed\" target=\"_blank\" id=\"16857549\">16857549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong GK, Joo DT, McDonnell C. Lipid resuscitation in a carnitine deficient child following intravascular migration of an eidural catheter. <i>Anaesthesia</i>. 2010;65(2):192-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/19849674/pubmed\" target=\"_blank\" id=\"19849674\">19849674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19282085\"></a>Young AC, Velez LI, Kleinschmidt KC. Intravenous fat emulsion therapy for intentional sustained-release verapamil overdose. <i>Resuscitation</i>. 2009;80(5):591-593.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/19282085/pubmed\" target=\"_blank\" id=\"19282085\">19282085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zellner DC, Iacono JM. &quot;Dilution anemia&quot; associated with multiple infusions of a fat emulsion. <i>Am J Clin Nutr</i>. 1967;20(7):766-776.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information/abstract-text/6036266/pubmed\" target=\"_blank\" id=\"6036266\">6036266</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 91658 Version 53.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F48869238\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F47022752\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F22549120\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F22788843\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F22781932\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F22781933\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22781934\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22781935\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F47022753\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F47022751\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F22781979\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F22781948\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F22549121\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25976338\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F22801480\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F22781923\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F22781924\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F47086803\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F47086800\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F22781921\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F22781922\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F22781938\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F22781951\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F22781927\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F22781929\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F48851915\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F50168918\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/91658|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-patient-drug-information\" class=\"drug drug_patient\">Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Patient drug information</a></li><li><a href=\"topic.htm?path=fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information\" class=\"drug drug_pediatric\">Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Pediatric drug information</a></li></ul></div></div>","javascript":null}